-
Company - Kronos Bio
About Us We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of therapeutics that target the dysregulated transcription that causes cancer and other serious di...
-
Science - Kronos Bio
Our Science Dysregulated transcription is the hallmark of cancer Kronos Bio is focused on developing medicines that target dysregulated transcription factor activity, a hallmark of cancer and other se...
-
Open Positions - Kronos Bio
Careers Join our team. We’re looking for individuals who want to join us as we seek to discover and develop new medicines. See our current list of openings below or submit your resume to careers@krono...
-
Clinical Trials - Kronos Bio
Clinical Trials At Kronos Bio, we are actively recruiting patients for three clinical trials evaluating our investigational therapies for cancer. We encourage you to learn more below or reach out to u...
-
Publications - Kronos Bio
Publications 2023 2022 2021 2020 2019 2018 2017 and older SLAS 2023 Walker, William, et. al., Small Molecule Microarray Screening Scale-Up and Automation at Kronos Bio ASH 2022 Carvajal, Luis A., et. ...
-
Phase 1/2 Study of KB-0742 in Solid Tumors - Kronos Bio
Phase 1/2 Study of KB-0742 in Solid Tumors A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma (NCT04718675) COMPOU...